NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis $2.96 -0.38 (-11.38%) Closing price 04:00 PM EasternExtended Trading$2.96 +0.00 (+0.17%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About LENZ Therapeutics Stock (NASDAQ:LENZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LENZ Therapeutics alerts:Sign Up Key Stats Today's Range$2.82▼$3.4450-Day Range$3.01▼$4.5252-Week Range$2.80▼$32.13Volume951,262 shsAverage Volume1.23 million shsMarket Capitalization$93.00 millionP/E RatioN/ADividend YieldN/APrice Target$14.75Consensus RatingHold Company Overview LENZ Therapeutics is a biopharmaceutical company focused on developing treatments for presbyopia, the age-related difficulty focusing on nearby objects. Its lead product, VIZZ (aceclidine ophthalmic solution), is a prescription eye drop approved in the United States for treating presbyopia in adults. VIZZ is designed to improve near vision by constricting the pupil, which can increase depth of focus. The company’s work centers on developing and commercializing this topical, non-invasive treatment as an alternative to corrective eyewear for people with presbyopia. LENZ became a publicly traded company in 2024 following a merger with Graphite Bio. Its business is focused on the U.S. market for presbyopia treatments.AI Generated. May Contain Errors. Read More LENZ Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreLENZ MarketRank™: 3.23132994086 of 5 starsLENZ Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 253rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingLENZ Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialLENZ Therapeutics has a consensus price target of $14.75, representing about 398.3% upside from its current price of $2.96.Amount of Analyst CoverageLENZ Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about LENZ Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for LENZ Therapeutics are expected to grow in the coming year, from ($4.08) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LENZ Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENZ Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted24.54% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in LENZ Therapeutics has recently decreased by 22.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. News and Social Media1.4 / 5News SentimentN/A News SentimentLENZ Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for LENZ Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for LENZ on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,134,778.00 in company stock.Percentage Held by Insiders8.30% of the stock of LENZ Therapeutics is held by insiders.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENZ Therapeutics' insider trading history. Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LENZ Stock News HeadlinesLENZ Therapeutics: Don't Be Tempted With This Value TrapNovember 13, 2026 | seekingalpha.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Has Consensus Target Price of $14.75November 12, 2026 | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 20 at 1:00 AM | Weiss Ratings (Ad)LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Split On VIZZNovember 4, 2026 | finance.yahoo.comLENZ Therapeutics (NASDAQ:LENZ) Major Shareholder Sells $9,134,778.24 in StockNovember 3, 2026 | insidertrades.comLENZ Therapeutics consensus price target decreased by 25% to $15.30November 3, 2026 | msn.comLENZ (LENZ) Q3 2026 Earnings Call TranscriptNovember 3, 2026 | finance.yahoo.comLENZ Therapeutics (LENZ) Stock Rallies As Q3 Results Expose Cash BurnOctober 30, 2026 | finance.yahoo.comSee More Headlines LENZ Stock Analysis - Frequently Asked Questions How have LENZ shares performed this year? LENZ Therapeutics' stock was trading at $16.00 at the beginning of the year. Since then, LENZ stock has decreased by 81.5% and is now trading at $2.96. How were LENZ Therapeutics' earnings last quarter? LENZ Therapeutics, Inc. (NASDAQ:LENZ) announced its quarterly earnings data on Wednesday, October, 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.10. The company earned $3.38 million during the quarter, compared to analyst estimates of $4.20 million. LENZ Therapeutics had a negative net margin of 1,134.97% and a negative trailing twelve-month return on equity of 59.56%. Read the conference call transcript. When did LENZ Therapeutics IPO? LENZ Therapeutics (LENZ) raised $224 million in an IPO on Thursday, June 24th 2021. The company issued 14,000,000 shares at $15.00-$17.00 per share. Who are LENZ Therapeutics' major shareholders? LENZ Therapeutics' top institutional shareholders include Blue Owl Capital Holdings LP (2.49%), State Street Corp (1.34%), Goldman Sachs Group Inc. (1.11%) and Marshall Wace LLP (0.92%). Insiders that own company stock include Ra Capital Management, LP, James W Mccollum, Daniel R Chevallard and Shawn Olsson. View institutional ownership trends. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LENZ Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Rocket Lab (RKLB), SoFi Technologies (SOFI), Robinhood Markets (HOOD), Applied Materials (AMAT) and Applied Digital (APLD). Company Calendar Last Earnings10/28/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (12m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 LENZ's financial health is in the Red zone, according to TradeSmith. LENZ has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CIK1815776 Webwww.lenz-tx.com Phone(858) 925-7000FaxN/AEmployees152Year Founded2013Price Target and Rating Average Price Target for LENZ Therapeutics$14.75 High Price Target$29.00 Low Price Target$5.00 Potential Upside/Downside+398.3%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($4.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.13 million Net Margins-1,134.97% Pretax Margin-1,134.93% Return on Equity-59.56% Return on Assets-54.75% Debt Debt-to-Equity RatioN/A Current Ratio11.66 Quick Ratio11.39 Sales & Book Value Annual Sales$19.09 million Price / Sales4.87 Cash FlowN/A Price / Cash FlowN/A Book Value$6.11 per share Price / Book0.48Miscellaneous Outstanding Shares31,420,000Free Float28,813,000Market Cap$93.00 million OptionableOptionable Beta0.78 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:LENZ) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.